ПРЕЭКЛАМПСИЯ, ФИБРОЗ И МАРИНОБУФАГЕНИН
PDF

Ключевые слова

преэклампсия
Na/K-ATФаза
маринобуфагенин
Fli1
коллаген-1
фиброз сосудов

Как цитировать

Агалакова, Н. И., Резник, В. А., Колодкин, Н. И., Тапильская, Н. И., & Багров, А. Я. (2020). ПРЕЭКЛАМПСИЯ, ФИБРОЗ И МАРИНОБУФАГЕНИН. Российский физиологический журнал им. И. М. Сеченова, 106(11), 1340–1349. https://doi.org/10.31857/S0869813920110023

Аннотация

Преэклампсия – это возникающее во время беременности и затрагивающее несколько систем органов потенциально опасное для жизни заболевание, которое характеризуется повышенным артериальным давлением матери и появлением белка в моче. Частота преэклампсии (3-7%) не снижается, и это заболевание по-прежнему занимает ведущее положение среди осложнений беременности. В этой статье мы представляем “фиброзную концепцию” патогенеза преэклампсии, которая включает в себя систему “Na/К-АТФаза-эндогенные ингибиторы” и в том числе маринобуфагенин зависимое угнетение фактора транскрипции Fli1. Новый подход к лечению преэклампсии включает в себя иммунонейтрализацию эндогенного маринобуфагенина.

https://doi.org/10.31857/S0869813920110023
PDF

Литература

Blaustein M.P. Sodium ions, calcium ions, blood pressure regulation and hypertension: а reassessment and a hypothesis. Am. J. Physiol. 232: C167-C173. 1977.

Buckalew V.M. Jr., Nelson D.B. Natriuretic and sodium transport inhibitory activity in plasma of volume-expanded dogs. Kidney Int. 5: 12-22. 1974.

De Wardener H.E., Clarkson E.N. A concept of natriuretic hormone. Physiol. Rev. 65: 658-759. 1985.

Bailly C. Effect of luminal atrial natriuretic peptide on chloride reabsorption in mouse cortical thick ascending limb: inhibition by endothelin. J. Am. Soc. Nephrol. 11: 1791-1797. 2000.

Bagrov A.Y., Shapiro J.I. Endogenous digitalis: pathophysiologic roles and therapeutic applications. Nature Clin. Pract. Nephrol. 4: 378-392. 2008.

Flier J., Edwards M.W., Daly J.W., Myers C.W. Widespread occurrence in frogs and toads of skin compounds interacting with the ouabain site of Na+,K+-ATPase. Science. 208(4443): 503-505. 1980.

Morris J.F., Ismail-Beigi F., Butler V.P. Jr., Gati I., Lichtstein D. Ouabain-sensitive Na+,K(+)-ATPase activity in toad brain. Comp. Biochem. Physiol. A Physiol. 18: 599-606. 1997.

Kieval R.S., Butler V.P. Jr., Derguini F., Bruening R.C., Rosen M.R. Cellular electrophysiologic effects of vertebrate digitalis-like substances. J. Am. Coll. Cardiol. 11: 637-643. 1988.

Goto A., Yamada K., Ishii M., Sugimoto T., Yoshioka M. Immunoreactivity of endogenous digitalis-like factors. Biochem. Pharmacol. 41: 1261-1263. 1991.

Bagrov A.Y., Fedorova O.V., Dmitrieva R.I., Howald W.N., Hunter A.P., Kuznetsova E.A., Shpen V.M. Bufodienolide nature of endogenous inhibitor of Na/K ATPase in the urine from patients with acute myocardial infarction. Hypertension. 31: 1097-1103. 1998.

Fedorova O.V., Simbirtsev A.S., Kolodkin N.I., Kotov A.Y., Agalakova N.I., Kashkin V.A., Tapilskaya N.I., Bzhelyansky A., Reznik V.A., Frolova E.V., Nikitina E.R., Budny G.V,. Longo D.L., Lakatta E.G., Bagrov A.Y. Monoclonal antibody to an endogenous bufadienolide, marinobufagenin, reverses preeclampsia-induced Na/K-ATPase inhibition and lowers blood pressure in NaCl-sensitive hypertension. J. Hypertens. 26: 2414–2425. 2008.

Fedorova O.V., Zernetkina V.I., Shilova V.Y., Grigorova Y.N., Juhasz O., Wei W., Marshall C.A., Lakatta E.G., Bagrov A.Y. Synthesis of an endogenous steroidal Na pump inhibitor marinobufagenin, implicated in human cardiovascular diseases, is initiated by CYP27A1 via bile acid pathway. Circulation: Cardiovasc. Genetics. 8: 736-745. 2015.

Fedorova O.V., Bagrov A.Y. Inhibition of Na/K ATPase from rat aorta by two endogenous Na/K pump inhibitors, ouabain and marinobufagenin. Evidence of interaction with different alpha-subinit isoforms. Am. J. Hypertens. 10: 929-935. 1997.

Bagrov A.Y., Fedorova O.V. Effects of two putative endogenous digitalis-like factors, marinobufagenin and ouabain, on the Na/K pump in human mesenteric arteries. J. Hypertens. 16: 1953-1958. 1998.

Fridman A.I., Matveev S.A., Agalakova N.I., Fedorova O.V., Lakatta E.G., Bagrov A.Y. Marinobufagenin, an endogenous ligand of alfa-1 Na/K-ATPase, is a marker of congestive heart failure severity. J. Hypertens. 20: 1189-1194. 2002.

Kolmakova E.V., Haller S.T., Kennedy D.J., Isachkina A.N., Budny G.V., Frolova E.V., Nikitina E.R., Piecha G., Malhotra D., Fedorova O.V., Shapiro J.I., Bagrov A.Y. Endogenous cardiotonic steroids in chronic renal failure. Nephrol. Dial. Transplantat. 26: 2912-2919. 2011.

Bagrov A.Y., Shapiro J.I., Fedorova O.V. Endogenous cardiotonic steroids: physiology, pharmacology and novel therapeutic targets. Pharmacol. Rev. 61: 9-38. 2009.

MacKay A.P., Berg C.J., Atrash H.K. Pregnancy-related mortality from preeclampsia and eclampsia. Obstet. Gynecol. 97: 533-538. 2001.

Sibai B., Dekker G., Kupferminc M. Pre-eclampsia. Lancet. 365: 785-799. 2005.

Thangaratinam S., Coomarasamy A., O'Mahony F., Sharp S., Zamora J., Khan K.S., Ismail K.M.K. Estimation of proteinuria as a predictor of complications of pre-eclampsia: a systematic review. BMC Med. 7: 10. 2009.

Wagner S.J., Craici I.M., Grande J.P., Garovic V.D. From placenta to podocyte: vascular and podocyte pathophysiology in preeclampsia. Clin. Nephrol. 78: 241-249. 2012.

Herse F., LaMarca B. Angiotensin II type 1 receptor autoantibody (AT1-AA)-mediated pregnancy hypertension. Am. J. Reprod. Immunol. 69: 413-418. 2013.

Meekins J.W., Pijnenborg R., Hanssens M., McFadyen I.R., van Asshe A. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br. J. Obstet. Gynaecol. 101: 669-674. 1994.

Gallery E.D.M., Hunyor S.M., Gyory A.Z. Plasma volume concentration: a significant factor in both pregnancy-associated hypertension (pre-eclampsia) and chronic hypertension in pregnancy. Q J Med. 192: 593-602. 1979.

Masilamani S., Baylis C. Pregnant rats are refractory to the natriuretic actions of ANP. Am. J. Physiol. 267: R1611-R1616. 1994.

Graves S.W. The possible role of digitalislike factors in pregnancy-induced hypertension. Hypertension. 10: 184-186. 1987.

Graves S.W., Valdes R. Jr., Brown B.A., Knight A.B., Craig H.R. Endogenous digoxin-immunoreactive substance in human pregnancies. J. Clin. Endocrinol. Metab. 58: 748-751. 1984.

Poston L., Morris J.F., Wolfe C.D., Hilton P.J. Serum digoxin-like substances in pregnancy-induced hypertension. Clin. Sci. (Lond). 77: 189-194. 1989.

Gilson G.J., Graves S.W., Qualls C.R., Curet L.B. Digoxin-like immunoreactive substance and sodium-potassium-adenosine triphosphatase inhibition in normal pregnancy: a longitudinal study. Obstet. Gynecol. 89: 743-746. 1997.

Goodlin R.C. Antidigoxin antibodies in eclampsia. New Engl. J. Med. 318: 518-519. 1988.

Kaminski K., Rechberger T. Concentration of digoxin-like immunoreactive substance in patients with preeclampsia and its relation to severity of pregnancy-induced hypertension. Am. J. Obstet. Gynecol. 165: 733-736, 1991.

Ujhelyi M.R, Robert S., Cummings D.M., Colucci R.D., Green P.J., Sailstad J., Vlasses P.H., Zarowitz B.J. Influence of digoxin immune Fab therapy and renal dysfunction on the disposition of total and free digoxin. Ann. Intern. Med. 119: 273-277. 1993.

Yamada K., Goto A., Hui C., Yagi N., Sugimoto T. Effects of the Fab fragment of digoxin antibody on the natriuresis and increase in blood pressure induced by intracerebroventricular infusion of hypertonic saline solution in rats. Clin. Sci. (Lond). 82: 625-630. 1992.

Krep H., Price D.A., Soszynski P., Tao Q.F., Graves S.W., Hollenberg N.K. Volume sensitive hypertension and the digoxin-like factor. Reversal by a Fab directed against digoxin in DOCA-salt hypertensive rats. Am. J. Hypertens. 8: 921-927. 1995.

Morris J.F., Poston L., Wolfe C.D., Hilton P.J. A comparison of endogenous digoxin-like immunoreactivity and sodium transport inhibitory activity in umbilical arterial and venous serum. Clin. Sci. (Lond). 75: 577-579.1988.

Di Grande A., Boura A.L., Read M.A., Malatino L.S., Walters W.A. Release of a substance from the human placenta having digoxin-like immunoreactivity. Clin. Exp. Pharmacol. Physiol. 20: 603-607. 1993.

Armler E., Cester N., Salvolini E., Staffolani R., Burkhard M., Mazzanti L., Kotyk A., Romanini C. Human hypertensive placenta contains an increased amount of Na,K-ATPase with higher affinity for cardiac glycosides. Cell Biol. Int. 18: 723-727. 1994.

Bagrov A.Y., Shapiro J.I., Fedorova O.V. Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets. Pharmacol. Rev. 61: 9-38. 2009.

Lopatin D.A., Ailamazian E.K., Dmitrieva R.I., Shpen V.M., Fedorova O.V., Doris P.A., Bagrov A.Y. Circulating bufodienolide and cardenolide sodium pump inhibitors in preeclampsia. J. Hypertens. 17: 1179-1187. 1999.

Averina I.V., Tapilskaya N.I., Reznik V.A., Frolova E.V., Fedorova O.V., Lakatta E.G., Bagrov A.Y. Endogenous Na/K-ATPase inhibitors in patients with preeclampsia. Cell. Mol. Biol. (Noisy-le-grand) 52: 19-23. 2006.

Fox H. Fibrosis of placental villi. J. Pathol. Bacteriol. 95: 573-579. 1968.

Hausvater A., Giannone T., Sandoval Y.H., Doonan R.J., Antonopoulos C.N., Matsoukis I.L., Petridou E.T., Daskalopoulou S.S. The association between preeclampsia and arterial stiffness. J. Hypertens. 30: 17-33. 2012.

Orabona R., Sciatti E., Vizzardi E., Bonadei I., Valcamonico A., Metra M., Frusca T. Endothelial dysfunction and vascular stiffness in women with previous pregnancy complicated by early or late pre-eclampsia. Ultrasound Obstet. Gynecol. 49: 116-123. 2017.

Trojanowska M. Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat. Rev. Rheumatol. 6: 453-460. 2010.

Elkareh J., Kennedy D.J., Yashaswi B., Vetteth S., Shidyak A., Kim E.G., Smaili S., Periyasamy S.M., Hariri I.M., Fedorova L., Liu J., Wu L., Kahaleh M.B., Xie Z., Malhotra D., Fedorova O.V., Kashkin V.A., Bagrov A.Y., Shapiro J.I. Marinobufagenin stimulates fibroblast collagen production and causes fibrosis in experimental uremic cardiomyopathy. Hypertension. 49: 215-224. 2007.

Elkareh J., Periyasamy S.M., Shidyak A., Vetteth S., Schroeder J., Raju V., Hariri I.M., El-Okdi N., Gupta S., Fedorova L., Liu J., Fedorova O.V., Kahaleh M.B., Xie Z., Malhotra D., Watson D.K, Bagrov A.Y., Shapiro J.I. Marinobufagenin induces increases in procollagen expression in a process involving protein kinase C and Fli-1: implications for uremic cardiomyopathy. Am. J. Physiol. Renal Physiol. 296: F1219-F1226. 2009.

Nikitina E.R., Mikhailov A.V., Nikandrova E.S., Frolova E.V., Fadeev A.V., Shman V.V., Shilova V.Y., Tapilskaya N.I., Shapiro J.I, Fedorova O.V., Bagrov A.Y. In preeclampsia endogenous cardiotonic steroids induce vascular fibrosis and impair relaxation of umbilical arteries. J. Hypertens. 29: 769-776. 2011.

Orabona R., Sciatti E., Vizzardi E., Bonadei I., Prefumo F., Valcamonico A., Metra M., Frusca T. Ultrasound evaluation of left ventricular and aortic fibrosis after pre-eclampsia. Ultrasound Obstet. Gynecol. 52: 648-653. 2018.

Fedorova O.V., Emelianov I.V., Bagrov K.A., Grigorova Y.N., Wei W., Juhasz O., Frolova E.V., Marshall C.A., Lakatta E.G., Konradi A.O., Bagrov A.Y. Marinobufagenin-induced vascular fibrosis is a likely target for mineralocorticoid antagonists. J. Hypertens. 33: 1602-1610. 2015.

Zhang Y., Wei W., Shilova V., Petrashevskaya N.N., Zernetkina V.I., Grigorova Y.N., Marshall C.A., Fenner R.C., Lehrmann E., Wood W.H. 3rd, Becker K.G., Lakatta E.G., Bagrov A.Y., Fedorova O.V. Monoclonal antibody to marinobufagenin downregulates TGFβ profibrotic signaling in left ventricle and kidney and reduces tissue remodeling in salt-sensitive hypertension. J. Am. Heart Assoc. 8: e012138. 2019.

Pruthi D., Khankin E.V., Blanton R.M., Aronovitz M., Burke S.D., McCurley A., Karumanchi S.A., Jaffe I.Z. Exposure to experimental preeclampsia in mice enhances the vascular response to future injury. Hypertension. 65: 863-870. 2015.

Adair C.D., Buckalew V.M., Graves S.W., Lam G.K., Johnson D.D., Saade G., Lewis D.F., Robinson C., Danoff T.M., Chauhan N., Hopoate-Sitake M., Porter K.B., Humphrey R.G, Trofatter K.F., Amon E., Ward S., Kennedy L., Mason L., Johnston J.A. Digoxin immune Fab treatment for severe preeclampsia. Am. J. Perinatol. 27: 655-662. 2010.

Adair C.D., Buckalew V., Taylor K., Ernest J.M., Frye A.H., Evans C., Veille J.C. Elevated endoxin-like factor complicating a multifetal second trimester pregnancy: treatment with digoxin-binding immunoglobulin. Am. J. Nephrol. 16: 529-531. 1996.

Krep H., Price D.A., Soszynski P., Tao Q-F., Graves S.W., Hollenberg N.K. Volume sensitive hypertension and the digoxin-like factor reversal by a fab directed against digoxin in DOCA-salt hypertensive rats. Am. J. Hypertens. 8: 921-927. 1995.

Chen K.K., Kovarikova A. Pharmacology and toxicology of toad venom. J. Pharm. Sci. 56: 1535-1541. 1967.

Hitt M., Ettinger D.D. Toad toxicity. New Eng. J. Med. 314: 1517-1518. 1986.

Brubacher J.R., Lachmanen D., Ravikumar P.R., Hoffman R.S. Efficacy of digoxin specific Fab fragments (Digibind) in the treatment of toad venom poisoning. Toxicology. 37: 931-942. 1999.

Agunanne E., Horvat D., Uddin M.N., Puschett J. The Treatment of Preeclampsia in a Rat Model Employing Digibind. Am. J. Perinatol. 27: 299-305. 2010.

Ma J., Esplin M.S., Adair C.D., Mason L.A., Graves S.W. Increasing evidence for and regulation of a human placental endogenous digitalis-like factor. Reprod. Sci. 19: 437-448. 2012.

Adair D., Hinshaw A., Russell G., Rose J., Veille J., Buckalew V. Effects of Fab digoxin-specific antibodies on mean arterial pressure in severe preeclampsia. Am. J. Hypertens. 10: 11A. 1997.

Hopoate-Sitake M., Adair C.D., Buckalew V.M., Johnson D.D., Lewis D.F., Robinson C.J., Saade G.R., Graves S.W. Digoxin antibody fragment, antigen binding (Fab), treatment of preeclampsia in women with endogenous digitalis-like factor: a secondary analysis of the DEEP Trial. Am. J. Obstet. Gynecol. 209: 119.e1-6. 2013.

Ishkaraeva-Yakovleva V.V., Fedorova O.V., Solodovnikova N.G., Frolova E.V., Bzhelyansky A.M., Emelyanov I.V., Adair C.D., Zazerskaya I.E., Bagrov A.Y. DigiFab interacts with endogenous cardiotonic steroids and reverses preeclampsia-induced Na/K-ATPase inhibition. Reprod. Sci. 19: 1260-1267. 2012.

Агалакова Н.И., Резник В.А., Надей О.В., Ершов И.А., Рассоха О.С., Васютина М.Л., Тапильская Н.И., Рухляда Н.Н., Галагудза М.М., Багров А.Я. Эндогенные кардиотонические стероиды и фиброз сосудов при преэклампсии. Артериальная гипертензия. 24: 684-692. 2018.[Agalakova N.I., Reznik V.A., Nadei O.V., Ershov I.A., Rassokha O.S., Vasyutina M.L., Tapilskaya N.I., Rukhliada N.N., Galagudza M.M., Bagrov A.Y. Endogenous cardiotonic steroids and vascular fibrosis in preeclampsia. Arterial Hypertension 24:684-692. 2018. (In Russ)].

Fedorova O.V., Ishkaraeva V.V., Grigorova Y.N., Reznik V.A., Kolodkin N.I., Zazerskaya I.E., Zernetkina V., Agalakova N.I., Tapilskaya N.I., Adair C.D., Lakatta E.G., Bagrov A.Y. Antibody to Marinobufagenin Reverses Placenta-Induced Fibrosis of Umbilical Arteries in Preeclampsia. Int. J. Mol. Sci. 19: 2377. 2018.

Tihtonen K.M., Kööbi T.T., Uotila J.T. Arterial stiffness in preeclamptic and chronic hypertensive pregnancies. Eur. J. Obst. Gynecol. Reprod. Biol. 128: 180-186. 2006.

Agalakova N.I., Reznik V.A., Nadei O.V., Ershov I.A., Rassokha O.S., Vasyutina M.L., Ivanov D.O., Adair E.D., Galagudza M.M., Bagrov A.Y. Antibody against Na/K-ATPase inhibitor lowers blood pressure and increases vascular Fli1 in experimental preeclampsia. Am. J. Hypertens. 33: 514-519. 2020.

Uddin M.N., Wages J.M., Pantho A.F., Larrick J.W., Drever N., Allen S.R., Kuehl. TJ. Novel anti-MBG antibodies protect cytotrophoblast cells from a marinobufagenin-induced preeclampsia phenotype. Am. J. Obstet. Gynecol. 218: S199. 2018.

Pullen M.A., Harpel M.R, Danoff T.M., Brooks D.P. Comparison of non-digitalis binding properties of digoxin-specific Fabs using direct binding methods. J. Immunol. Methods. 31: 235-241. 2008.

Pullen M.A., Brooks D.P., Edwards R.M. Characterization of the neutralizing activity of digoxin-specific Fab toward ouabain-like steroids. J. Pharmacol. Exp. Ther. 310: 319-325. 2004.

Fedorova O.V., Tapilskaya N.I., Bzhelyansky A.M., Frolova E.V., Nikitina E.R., Reznik V.A., Kashkin V.A., Bagrov A.Y. Interaction of Digibind with endogenous cardiotonic steroids from preeclamptic placentae. J. Hypertens. 28: 361-366. 2010.